Faron Pharmaceuticals Oy - Finland-based biopharmaceutical company with a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy - Latest data from four cohorts in ongoing phase 1/2 Matins clinical trial of cancer drug bexmarilimab demonstrate early signs of efficacy. This allows these cohorts - cutaneous melanoma, ovarian cancer, colorectal cancer, and hepatocellular cancer - to move the part 3. Further data from all part 2 cohorts will help Faron evaluate which indications should be continue further in development.
Obtains approval for expanding Matins to include another two colorectal cancer cohorts receiving 1 milligram per kilogram dosed as weekly of two week intervals, with recruitment having begun and results due in first half of 2021. Plans to start neoadjuvant bexmarilimab study in colorectal cancer and clear cell renal cell carcinoma, also plans to expand bexmarilimab programme to evaluate its safety and efficacy in a pilot study in combination with anti-PD-(L)1 therapy in non-small cell lung carcinoma. Additionaly plans to start a phase 1/2 bexmarilimab study in combination with standard of care in acute myeloid leukaemia/myelodysplastic syndrome patients in second half of 2021.
Current stock price: 285.50 pence
Year-to-date change: up 8.8%
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Faron Pharma (FARN)